Atuss
NDC Package 15370-140-04
Package Information
Atuss is this combination medication is used to relieve symptoms caused by the common cold, flu, allergies, "hay fever," and other breathing illnesses (such as sinusitis, bronchitis). Marketed by Carwin Pharmaceutical Associates, Llc, this product is identified by NDC 15370-140 and is authorized under FDA application part341.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 15370 - Carwin Pharmaceutical Associates, Llc
- 15370-140 - Atuss
- 15370-140-04 - 118 mL in 1 BOTTLE, PLASTIC
- 15370-140 - Atuss
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (15370-140). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 15370-140-04 identifies a specific commercial package of 118 ml in 1 bottle, plastic of Atuss DA, labeled by Carwin Pharmaceutical Associates, Llc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Carwin Pharmaceutical Associates, Llc on October 25, 2016. The current certification is valid through January 16, 2023.
What are the primary indications for this medication?
This combination medication is used to relieve symptoms caused by the common cold, flu, allergies, "hay fever," and other breathing illnesses (such as sinusitis, bronchitis). These symptoms include cough, watery eyes, itchy eyes/nose/throat, runny nose, and sneezing. This product contains a cough suppressant (such as chlophedianol) that affects a certain part of the brain, reducing the urge to cough. This product also contains a decongestant (such as pseudoephedrine, phenylephrine), which helps relieve stuffy nose symptoms. It also contains an antihistamine (such as brompheniramine, triprolidine, among others), which helps relieve watery eyes, itchy eyes/nose/throat, runny nose, and sneezing. This medication is not usually used for ongoing coughs from smoking, asthma, or other long-term breathing problems (such as emphysema), or for coughs with a lot of mucus, unless directed by your doctor. Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. Therefore, do not use this product to treat cold symptoms in children younger than 6 years unless specifically directed by the doctor. Some products (such as long-acting tablets/capsules) are not recommended for use in children younger than 12 years. Ask your doctor or pharmacist for more details about using your product safely. These products do not cure or shorten the length of the common cold and may cause serious side effects. To decrease the risk for serious side effects, carefully follow all dosage directions. Do not use this product to make a child sleepy. Do not give other cough-and-cold medication that might contain the same or similar ingredients (see also Drug Interactions section). Ask the doctor or pharmacist about other ways to relieve cough and cold symptoms
How is this Carwin Pharmaceutical Associates, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 15370014004. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.